levonorgestrel

Summary

Summary: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.

Top Publications

  1. ncbi Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel
    Hans Joachim Ahrendt
    Gynekologická a Porodnická Ambulance, Prague, Czech Republic
    Contraception 80:436-44. 2009
  2. ncbi Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas
    M Valeria Bahamondes
    Department of Obstetrics and Gynecology, University of Campinas, Campinas, Brazil
    Contraception 84:e11-6. 2011
  3. pmc Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database
    Lianne Parkin
    Department of Preventive and Social Medicine, Dunedin School of Medicine, University of Otago, New Zealand
    BMJ 342:d2139. 2011
  4. ncbi Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis
    Ioannis D Gallos
    Academic Unit of Obstetrics and Gynaecology, Birmingham Women s Hospital, Birmingham, UK
    Am J Obstet Gynecol 203:547.e1-10. 2010
  5. ncbi Levonorgestrel intrauterine system versus medical therapy for menorrhagia
    Janesh Gupta
    School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, United Kingdom
    N Engl J Med 368:128-37. 2013
  6. ncbi Use of the levonorgestrel releasing-intrauterine system in nulliparous women--a non-interventional study in Sweden
    Lena Marions
    Department of Obstetrics and Gynaecology, Division of Women s and Children s Health, Karolinska University Hospital Institutet, Stockholm, Sweden
    Eur J Contracept Reprod Health Care 16:126-34. 2011
  7. pmc Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9
    Øjvind Lidegaard
    Gynaecological Clinic 4232, Rigshospitalet, University of Copenhagen, Denmark
    BMJ 343:d6423. 2011
  8. ncbi Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study
    S Middeldorp
    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Thromb Haemost 84:4-8. 2000
  9. ncbi Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue
    Yesim Bayoglu Tekin
    Department of Obstetric and Gynecology, Agri Patnos Public Hospital, Ministry of Health, Patnos Agri, Turkey
    Fertil Steril 95:492-6. 2011
  10. pmc Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data
    Susan S Jick
    Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, MA 02421, USA
    BMJ 342:d2151. 2011

Detail Information

Publications261 found, 100 shown here

  1. ncbi Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel
    Hans Joachim Ahrendt
    Gynekologická a Porodnická Ambulance, Prague, Czech Republic
    Contraception 80:436-44. 2009
    ..E2V/DNG; administered using a dynamic dosing regimen) with a monophasic OC containing ethinyl estradiol 20 mcg/levonorgestrel 100 mcg (EE/LNG). E2V releases estradiol (E2), which is identical to endogenously produced 17beta-estradiol.
  2. ncbi Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas
    M Valeria Bahamondes
    Department of Obstetrics and Gynecology, University of Campinas, Campinas, Brazil
    Contraception 84:e11-6. 2011
    Despite the high contraceptive efficacy and the additional noncontraceptive benefits of the levonorgestrel-releasing intrauterine system (LNG-IUS), concerns persist with respect to its use in nulligravidas...
  3. pmc Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database
    Lianne Parkin
    Department of Preventive and Social Medicine, Dunedin School of Medicine, University of Otago, New Zealand
    BMJ 342:d2139. 2011
    To examine the risk of non-fatal idiopathic venous thromboembolism in current users of a combined oral contraceptive containing drospirenone, relative to current users of preparations containing levonorgestrel.
  4. ncbi Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis
    Ioannis D Gallos
    Academic Unit of Obstetrics and Gynaecology, Birmingham Women s Hospital, Birmingham, UK
    Am J Obstet Gynecol 203:547.e1-10. 2010
    To conduct a systematic review and metaanalysis of studies evaluating the regression rate of endometrial hyperplasia with oral progestogens and levonorgestrel-releasing intrauterine system.
  5. ncbi Levonorgestrel intrauterine system versus medical therapy for menorrhagia
    Janesh Gupta
    School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, United Kingdom
    N Engl J Med 368:128-37. 2013
    ..In a pragmatic, multicenter, randomized trial, we compared the levonorgestrel-releasing intrauterine system (levonorgestrel-IUS) with usual medical treatment in women with menorrhagia who ..
  6. ncbi Use of the levonorgestrel releasing-intrauterine system in nulliparous women--a non-interventional study in Sweden
    Lena Marions
    Department of Obstetrics and Gynaecology, Division of Women s and Children s Health, Karolinska University Hospital Institutet, Stockholm, Sweden
    Eur J Contracept Reprod Health Care 16:126-34. 2011
    To evaluate the insertion procedure and continuation rates of the levonorgestrel releasing-intrauterine system (LNG-IUS) in nulliparous women who, due to fear of complications, are often denied this very effective contraceptive method.
  7. pmc Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9
    Øjvind Lidegaard
    Gynaecological Clinic 4232, Rigshospitalet, University of Copenhagen, Denmark
    BMJ 343:d6423. 2011
    ..To assess the risk of venous thromboembolism from use of combined oral contraceptives according to progestogen type and oestrogen dose...
  8. ncbi Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study
    S Middeldorp
    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Thromb Haemost 84:4-8. 2000
    ..28 healthy volunteers was to assess potential differences between the effects of an OC containing 150 microg levonorgestrel (as representative of the so-called second generation OC) and an OC containing 150 microg desogestrel (as ..
  9. ncbi Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue
    Yesim Bayoglu Tekin
    Department of Obstetric and Gynecology, Agri Patnos Public Hospital, Ministry of Health, Patnos Agri, Turkey
    Fertil Steril 95:492-6. 2011
    To compare efficacy of the levonorgestrel-releasing intrauterine system (LNG-IUS; Mirena) with depot GnRH analogue (GnRH-a; gosareline acetate; Zoladex) on endometriosis-related chronic pelvic pain (CPP) in patients with severe ..
  10. pmc Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data
    Susan S Jick
    Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, MA 02421, USA
    BMJ 342:d2151. 2011
    To compare the risk of non-fatal venous thromboembolism in women receiving oral contraceptives containing drospirenone with that in women receiving oral contraceptives containing levonorgestrel.
  11. ncbi Therapeutic levels of levonorgestrel detected in blood plasma of fish: results from screening rainbow trout exposed to treated sewage effluents
    Jerker Fick
    Department of Chemistry, Umea University, Umea, Sweden
    Environ Sci Technol 44:2661-6. 2010
    ..The progestin pharmaceutical levonorgestrel was detected in fish blood plasma at concentrations (8...
  12. ncbi The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review
    Andrew M Kaunitz
    Department of Obstetrics and Gynecology, University of Florida College of Medicine Jacksonville, FL 32209, USA
    Drugs 72:193-215. 2012
    ..databases to evaluate the clinical evidence and provide an update on the risks and benefits of using the levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of HMB...
  13. ncbi Long-term treatment of menorrhagia with levonorgestrel intrauterine system versus endometrial resection
    Ilkka Rauramo
    The Finnish Medical Society Duodecim, Helsinki, Finland
    Obstet Gynecol 104:1314-21. 2004
    The purpose of this study was to compare the long-term efficacy of the levonorgestrel intrauterine system and transcervical resection of the endometrium in the treatment of menorrhagia.
  14. ncbi Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study
    Satu Suhonen
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, P O Box 610, 00029 HUS, Helsinki, Finland
    Contraception 69:407-12. 2004
    ..out at family-planning clinics of two university hospitals to compare the safety and acceptability of a levonorgestrel-releasing intrauterine system (LNG IUS) and oral contraceptives (OCs) in young nulliparous women...
  15. ncbi Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers
    T Kucuk
    Department of Obstetrics and Gynecology, GATA School of Medicine, Ankara, Turkey
    Clin Exp Obstet Gynecol 35:57-60. 2008
    ..To compare the efficacy of three progestin regimens in perimenopausal menorrhagia...
  16. ncbi Bleeding pattern and safety of consecutive use of the levonorgestrel-releasing intrauterine system (LNG-IUS)--a multicentre prospective study
    K Gemzell-Danielsson
    Department of Obstetrics and Gynaecology, Karolinska University Hospital, Stockholm, Sweden
    Hum Reprod 25:354-9. 2010
    ..Thus, many women use the LNG-IUS consecutively. However, published data on the bleeding pattern regarding consecutive use of the LNG-IUS is scarce...
  17. ncbi The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device
    Astrid van Hylckama Vlieg
    Department of Clinical Epidemiology, Leiden University Medical Center, C7 P, PO Box 9600, NL 2300 RC Leiden, The Netherlands
    Arterioscler Thromb Vasc Biol 30:2297-300. 2010
    ..of venous thrombosis associated with nonoral contraceptives (ie, injectable depot-medroxyprogesterone acetate contraceptives, hormone [levonorgestrel]-releasing intrauterine devices, a contraceptive patch, or a contraceptive implant).
  18. pmc Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine system (Mirena) for treatment of heavy menstrual bleeding: cost effectiveness analysis
    T E Roberts
    Health Economics Unit, School of Health and Population Sciences, Public Health Building, University of Birmingham, UK
    BMJ 342:d2202. 2011
    To undertake a cost effectiveness analysis comparing first and second generation endometrial ablative techniques, hysterectomy, and the levonorgestrel releasing intrauterine system (Mirena) for treating heavy menstrual bleeding.
  19. ncbi transient scrotal hyperthermia and levonorgestrel enhance testosterone-induced spermatogenesis suppression in men through increased germ cell apoptosis
    Christina Wang
    Department of Medicine, Harbor University of California, Los Angeles, Torrance, California 90509, USA
    J Clin Endocrinol Metab 92:3292-304. 2007
    ..In rodents and monkeys, a combination of hormonal and physical agents accelerates germ cell death...
  20. ncbi Proteomic analysis of testis biopsies in men treated with injectable testosterone undecanoate alone or in combination with oral levonorgestrel as potential male contraceptive
    Yugui Cui
    Laboratory of Reproductive Medicine, Department of Histology and Embryology, and Center of Clinical Reproductive Medicine, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China
    J Proteome Res 7:3984-93. 2008
    Treatment with injectable testosterone undecanoate (TU) alone or in combination with oral levonorgestrel (LNG) resulted in marked decreases in sperm concentrations...
  21. ncbi A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel
    J Endrikat
    Schering AG, Berlin, Germany
    Eur J Contracept Reprod Health Care 7:79-90. 2002
    ..pharmacokinetics of a dose-reduced oral contraceptive containing 20 microg ethinylestradiol (EE) + 100 microg levonorgestrel (LNG) in 18 young, healthy females...
  22. ncbi Pharmacokinetic study of different dosing regimens of levonorgestrel for emergency contraception in healthy women
    Elof Johansson
    Center for Biomedical Research, The Population Council, New York, NY, USA
    Hum Reprod 17:1472-6. 2002
    b>Levonorgestrel (LNG) is a commonly used progestin for emergency contraception; however, little is known about its pharmacokinetics and optimal dose for use.
  23. ncbi The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up study
    Oskari Heikinheimo
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
    Am J Obstet Gynecol 204:126.e1-4. 2011
    We sought to assess the effects of long-term use and safety of the levonorgestrel-releasing (LNG)-intrauterine system (IUS) among human immunodeficiency virus (HIV)-infected women in comparison with HIV-infected women not using the device.
  24. ncbi Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia
    A Kriplani
    Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
    Int J Gynaecol Obstet 97:190-4. 2007
    To evaluate the efficacy, acceptability, and possible side effects of a levonorgestrel-releasing intrauterine system for menorrhagia.
  25. ncbi The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease
    F B Lockhat
    Department of Obstetrics and Gynaecology, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, UK
    Hum Reprod 19:179-84. 2004
    ..A progestogen (levonorgestrel) administered via an intrauterine system (Lng-IUS) has been demonstrated to improve symptoms of endometriosis; ..
  26. ncbi Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis
    Anna F Glasier
    National Health Service Lothian, Edinburgh, UK
    Lancet 375:555-62. 2010
    ..We compared the efficacy and safety of ulipristal acetate with levonorgestrel for emergency contraception.
  27. ncbi A randomized trial to compare 24 h versus 12 h double dose regimen of levonorgestrel for emergency contraception
    Suk Wai Ngai
    Department of Obstetrics and Gynecology, University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong SAR, China
    Hum Reprod 20:307-11. 2005
    b>Levonorgestrel (0.75 mg given for two doses 12 h apart) has been proven to be an effective regimen for emergency contraception when the first dose is given within 72 h of unprotected coitus...
  28. ncbi Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel
    Susan S Jick
    Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, MA 02421, USA
    Contraception 73:566-70. 2006
    ..have about twice the risk for venous thromboembolism (VTE) compared to users of older OCs containing levonorgestrel. Estimates of the risk for VTE among users of norgestimate-containing OCs compared to other OCs, however, are ..
  29. ncbi Double-blind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine system
    Oskari Heikinheimo
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
    Contraception 81:481-6. 2010
    ..Misoprostol has been studied intensively to produce cervical dilatation. To date, no studies have evaluated the effectiveness, safety or acceptability of this treatment for repeat intrauterine device insertions...
  30. pmc Hysterectomy, endometrial destruction, and levonorgestrel releasing intrauterine system (Mirena) for heavy menstrual bleeding: systematic review and meta-analysis of data from individual patients
    L J Middleton
    Birmingham Clinical Trials Unit, University of Birmingham, Birmingham B15 2TT
    BMJ 341:c3929. 2010
    ..endometrial destruction (both "first generation" hysteroscopic and "second generation" non-hysteroscopic techniques), and the levonorgestrel releasing intrauterine system (Mirena) in the treatment of heavy menstrual bleeding.
  31. ncbi Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial
    Andrew M Kaunitz
    Department of Obstetrics and Gynecology, University of Florida College of Medicine Jacksonville, Jacksonville, Florida, USA
    Obstet Gynecol 116:625-32. 2010
    To compare the efficacy and safety of the levonorgestrel-releasing intrauterine system and oral medroxyprogesterone acetate in the treatment of idiopathic heavy menstrual bleeding.
  32. pmc Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis
    H Jick
    Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, MA 02421, USA
    BMJ 321:1190-5. 2000
    To compare the risk of idiopathic venous thromboembolism among women taking third generation oral contraceptives (with gestodene or desogestrel) with that among women taking oral contraceptives with levonorgestrel.
  33. ncbi A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia
    Jan Endrikat
    Bayer Inc, Toronto, Ontario, Canada
    J Obstet Gynaecol Can 31:340-7. 2009
    To evaluate the efficacy of a levonorgestrel-releasing intrauterine system (LNG-IUS) compared with a combined oral contraceptive containing 1 mg norethindrone acetate and 20 mg ethinyl estradiol (OC1/20) in reducing menstrual blood loss (..
  34. ncbi Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?
    Viveca Odlind
    Department of Obstetrics and Gynecology, Karolinska Hospital, Stockholm, Sweden
    Acta Obstet Gynecol Scand 81:482-90. 2002
    ..The aim of this article is to discuss sex hormone binding globulin (SHBG) as a marker of estrogenicity and as a surrogate indicator for the potential risk of VTE in users of COC...
  35. ncbi Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial
    Mamdouh M Shaaban
    Faculty of Medicine, Department of Obstetrics and Gynecology, Assiut University, Assiut 71526, Egypt
    Contraception 83:48-54. 2011
    This study compared the efficacy of the levonorgestrel-releasing intrauterine system (LNG-IUS) to low dose combined oral contraceptive pills (COC) in the management of idiopathic menorrhagia.
  36. ncbi Expressions of steroid receptors and Ki67 in first-trimester decidua and chorionic villi exposed to levonorgestrel used for emergency contraception
    Chun Xia Meng
    Department of Woman and Child Health, Division of Obstetrics and Gynecology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Fertil Steril 91:1420-3. 2009
    b>Levonorgestrel (1.5 mg) is commonly used for emergency contraception to prevent an unwanted pregnancy after an unprotected intercourse. We found that postovulatory administration of 1...
  37. ncbi A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment
    D Thiboutot
    Division of Dermatology, Pennsylvania State University, Hershey, USA
    Fertil Steril 76:461-8. 2001
    OBJECTIVE: To evaluate the efficacy of a low-dose oral contraceptive (OC) containing 100 microg of levonorgestrel (LNG) and 20 microg of ethinyl estradiol (EE) compared with placebo for the treatment of moderate acne...
  38. ncbi Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis
    L Fedele
    Department of Maternal and Child Health, Biology and Genetics, University of Verona, Verona, Italy
    Fertil Steril 75:485-8. 2001
    To evaluate the effectiveness of a levonorgestrel-releasing IUD as therapy for endometriosis of the rectovaginal septum.
  39. ncbi Intrauterine devices and adolescents
    Melanie A Gold
    Division of Adolescent Medicine, Department of Pediatrics, University of Pittsburgh School of Medicine, PA 15213, USA
    Curr Opin Obstet Gynecol 20:464-9. 2008
    ..The purpose of this review is to inform the reader of new information published on intrauterine devices (IUDs) and adolescents...
  40. ncbi Economic evaluation of the levonorgestrel-releasing intrauterine system for the treatment of dysfunctional uterine bleeding in Spain
    I Lete
    Gynaecology Department, Hospital Santiago Apóstol of Vitoria, Spain
    Eur J Obstet Gynecol Reprod Biol 154:71-80. 2011
    To compare the cost and effectiveness of the levonorgestrel-releasing intrauterine system (LNG-IUS) versus combined oral contraception (COC) and progestogens (PROG) in first-line treatment of dysfunctional uterine bleeding (DUB) in Spain.
  41. ncbi Levonorgestrel subdermal implants. A review of contraceptive efficacy and acceptability
    A J Coukell
    Adis International Limited, Auckland, New Zealand
    Drugs 55:861-87. 1998
    b>Levonorgestrel 6-capsule subdermal implants (Norplant) are an effective form of reversible contraception. When implanted under the skin of the upper arm, they release drug into the circulation at a relatively constant rate over 5 years...
  42. ncbi Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up
    Ioannis D Gallos
    School of Clinical and Experimental Medicine, University of Birmingham, Birmingham Women s Hospital, 3rd Floor, Birmingham B15 2TG, UK
    Hum Reprod 28:1231-6. 2013
    What is the risk of relapse for women with endometrial hyperplasia treated with levonorgestrel-releasing intrauterine system (LNG-IUS) or oral progestogens?
  43. pmc The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects
    Sanna Palovaara
    Department of Pharmacology and Clinical Pharmacology, University of Turku, Turku, Finland
    Br J Clin Pharmacol 56:232-7. 2003
    To study the effect of an oral contraceptive (OC) formulation containing ethinyloestradiol and levonorgestrel (LNG) (combination OC) or LNG alone on the CYP2C19-mediated hydroxylation of omeprazole in healthy females.
  44. ncbi Levonorgestrel intrauterine system: a first-line medical treatment for heavy menstrual bleeding
    Anita L Nelson
    David Geffen School of Medicine at UCLA, Torrance, CA, USA
    Womens Health (Lond Engl) 6:347-56. 2010
    ..The recent US FDA approval of the levonorgestrel-releasing intrauterine system as an indicated treatment for heavy menstrual bleeding in women who want to use ..
  45. ncbi The progestative effect of the levonorgestrel-releasing intrauterine system--when does it manifest?
    Y Zalel
    The Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Ramat Gan, 52621, Tel Hashomer, Israel
    Contraception 67:473-6. 2003
    ..study was to evaluate, clinically and sonographically, the time required for the progestative effect of the levonorgestrel-releasing intrauterine system (IUS, Mirena) to be manifested...
  46. pmc In vitro assessment of some sperm function following exposure to levonorgestrel in human fallopian tubes
    Alexia Hermanny
    Human Reproduction Unit, Department of Obstetrics and Gynecology, School of Medicine, University of Campinas, 13084 971 Campinas, SP, Brazil
    Reprod Biol Endocrinol 10:8. 2012
    The mechanism of action of levonorgestrel (LNG) as emergency contraception (EC) remains a subject of debate and its effect on sperm function has been only partially explained...
  47. ncbi Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system
    Anne Orbo
    Institute of Medical Biology, University of Tromsø, Norway
    Acta Obstet Gynecol Scand 89:1438-46. 2010
    To investigate whether regression of endometrial hyperplasia observed after 3 months of treatment with levonorgestrel impregnated intrauterine system device (LNG-IUS) was sustained after 6 months and whether these effects were still ..
  48. ncbi The levonorgestrel intrauterine system: therapeutic aspects
    T Luukkainen
    Steroid Research Laboratory, Institute of Biomedicine, P O Box 8, FIN 00014 University of Helsinki, Helsinki, Finland
    Steroids 65:699-702. 2000
    Use of the levonorgestrel-releasing intrauterine system (LNG IUS) is associated with a strong reduction in the number of days of bleeding and menstrual blood loss...
  49. ncbi Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study
    Wolfgang Junge
    Laboratorium fuer Klinische Forschung, Kiel, Germany
    Clin Drug Investig 31:573-84. 2011
    ..The objective of this study was to compare the metabolic and haemostatic effects of a novel COC comprising estradiol valerate/dienogest (E(2)V/DNG) with ethinylestradiol/levonorgestrel (EE/LNG).
  50. ncbi Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size
    T Foulon
    Départment de Biologie Intégrée, CHU, BP217, Grenoble Cedex 09, France
    Contraception 64:11-6. 2001
    ..most frequently given in our area, monophasic desogestrel/ethinylestradiol (DG/EE) and triphasic levonorgestrel/ethinylestradiol (LNG/EE), on lipoprotein parameters, especially LDL particle size and HDL subclass ..
  51. ncbi The synthetic gestagen levonorgestrel impairs metamorphosis in Xenopus laevis by disruption of the thyroid system
    Claudia Lorenz
    Department of Ecophysiology and Aquaculture, Leibniz Institute of Freshwater Ecology and Inland Fisheries, 12587 Berlin, Germany
    Toxicol Sci 123:94-102. 2011
    Synthetic gestagens, including levonorgestrel (LNG), are active compounds in contraceptives, and several studies report their occurrence in surface waters...
  52. ncbi Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts
    Peter C Reid
    Luton and Dunstable NHS Trust, Luton, UK
    BJOG 112:1121-5. 2005
    To compare the efficacy and tolerability of the levonorgestrel intrauterine system (LNG IUS) with mefenamic acid in the management of objective idiopathic menorrhagia.
  53. ncbi A potent ruthenium(II) antitumor complex bearing a lipophilic levonorgestrel group
    Jose Ruiz
    Departamento de Quimica Inorganica, Universidad de Murcia, 30071, Murcia, Spain
    Inorg Chem 50:9164-71. 2011
    ..The act of conjugating a levonorgestrel group to a ruthenium(II) complex resulted in synergistic effects between the metallic center and the steroidal ..
  54. ncbi Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system
    M Valeria Bahamondes
    Human Reproduction Unit, Department of Obstetrics and Gynaecology, School of Medical Sciences, University of Campinas and National Institute of Hormones and Women s Health, Caixa Postal 6181, 13084 971 Campinas, SP, Brazil
    Hum Reprod 25:1158-64. 2010
    The levonorgestrel-releasing intrauterine system (LNG-IUS) induces amenorrhoea, and its effect on bone mineral density (BMD) may constitute a concern. This study evaluated BMD in long-term users of the LNG-IUS or intrauterine device (IUD).
  55. ncbi Predictors of bleeding and user satisfaction during consecutive use of the levonorgestrel-releasing intrauterine system
    O Heikinheimo
    Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, PO Box 610, 00029 HUS Helsinki, Finland
    Hum Reprod 25:1423-7. 2010
    Consecutive use of the levonorgestrel-releasing intrauterine system (LNG-IUS) is increasing. However, little is known about factors that predict the bleeding during consecutive use...
  56. ncbi Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers
    Sreeraj Macha
    Clinical Pharmacokinetics and Pharmacodynamics, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT 06877, USA
    Clin Drug Investig 33:351-7. 2013
    ..Oral contraceptives may be co-administered with antidiabetic agents over long periods of time, therefore potential drug-drug interactions between oral contraceptives and antidiabetic drugs should be investigated...
  57. ncbi Acceptability of levonorgestrel subdermal implants versus tubal ligation for long-term contraception in a rural population of Zimbabwe
    M J Mitchel
    The Salvation Army Howard Hospital, 45 Josiah Chinamano Avenue, Harare, Zimbabwe
    Contraception 70:483-6. 2004
    This prospective cohort study of 257 rural Zimbabwean women was designed to compare patient satisfaction with levonorgestrel subdermal implants (Norplant and reg;) versus tubal ligation (TL) as a method of long-term contraception...
  58. ncbi The effect of the levonorgestrel-releasing intrauterine system and the copper intrauterine device on subendometrial microvascularization and uterine artery blood flow
    Mirela Foresti Jiménez
    Faculdade de Medicina, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil
    Fertil Steril 90:1574-8. 2008
    To evaluate the effect of the levonorgestrel intrauterine system (LNG-IUS) and TCU 380A on the subendometrial vascularization and the uterine artery blood flow during the midluteal phase.
  59. ncbi Depressive symptoms as predictors of discontinuation of treatment of menorrhagia by levonorgestrel-releasing intrauterine system
    Marko Elovainio
    National Research and Development Centre for Welfare and Health, P O Box 220, FIN 00531, Helsinki, Finland
    Int J Behav Med 14:70-5. 2007
    It has been shown that levonorgestrel-releasing intrauterine system (LNG-IUS) is an effective treatment of menorrhagia...
  60. ncbi Acceptability of the levonorgestrel-releasing intrauterine system after discontinuation of previous contraception: results of a French clinical study in women aged 35 to 45 years
    J B Dubuisson
    Service de Chirurgie Gynecologique, Clinique Universitaire Baudelocque, CHU Cochin Saint Vincent de Paul, Paris, Cedex, France
    Contraception 66:121-8. 2002
    This open, noncomparative study evaluated the rate of premature removals of the levonorgestrel-releasing intrauterine system (LNG-IUS) Mirena because of adverse events...
  61. ncbi Levonorgestrel-releasing intrauterine system versus conventional medical therapy for heavy menstrual bleeding in the Asia-Pacific region
    Byung S Lee
    Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Republic of Korea
    Int J Gynaecol Obstet 121:24-30. 2013
    ..cumulative continuation rate (CCR), in the treatment of idiopathic heavy menstrual bleeding (HMB) with the levonorgestrel-releasing intrauterine system (LNG-IUS) and with conventional medical therapies (CMTs), including combined ..
  62. ncbi Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers
    Willi Cawello
    Global Biostatistics, UCB Pharma, Monheim am Rhein, Germany
    Epilepsia 54:530-6. 2013
    To determine whether the antiepileptic drug lacosamide affects the pharmacokinetics or pharmacodynamics of a combined oral contraceptive (OC; ethinylestradiol 0.03 mg plus levonorgestrel 0.15 mg).
  63. ncbi Mirena (Levonorgestrel intrauterine system): a successful novel drug delivery option in contraception
    Susan Rose
    Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, 50 North Medical Drive, Suite 2B200, Salt Lake City, Utah 84132, USA
    Adv Drug Deliv Rev 61:808-12. 2009
    This manuscript serves as a review of Mirena, the levonorgestrel intrauterine system (LNG IUS) as a very successful drug delivery system. The LNG IUS has a very high contraceptive efficacy rate, and low rates of patient discontinuation...
  64. ncbi Comparison of uterine artery blood flow with levonorgestrel intrauterine system and copper intrauterine device
    Berna Haliloglu
    Department of Obstetrics and Gynecology, Faculty of Medicine, Maltepe University, 34843 Istanbul, Turkey
    Contraception 83:578-81. 2011
    As a contraceptive method, we investigated whether the levonorgestrel-releasing intrauterine system (LNG-IUS) has any effect on uterine artery blood flow when compared with copper intrauterine device (IUD).
  65. ncbi Pregnancy outcome after levonorgestrel-only emergency contraception failure: a prospective cohort study
    Lin Zhang
    International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200030, China
    Hum Reprod 24:1605-11. 2009
    b>Levonorgestrel (LNG), as a dedicated emergency contraception (EC) product, has been available over-the-counter in China for 10 years. Until now, only a small number of deliveries after LNG-EC failure have been documented.
  66. ncbi The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review
    Melissa J Buttini
    Wesley Medical Centre, Auchenflower, Queensland, Australia
    Aust N Z J Obstet Gynaecol 49:316-22. 2009
    The levonorgestrel intrauterine system (LNG-IUS) provides effective contraception and treatment for menorrhagia and is used to prevent endometrial hyperplasia (EH) in women taking unopposed oestrogens.
  67. ncbi [Effects of levonorgestrel-releasing intrauterine system on pain and recurrence associated with endometriosis and adenomyosis]
    Shan Deng
    Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China
    Zhonghua Fu Chan Ke Za Zhi 41:664-8. 2006
    To observe the effects of levonorgestrel-releasing intrauterine system (LNG-IUS) in treatment of pain associated with endometriosis (EM) and adenomyosis (AM), and in prevention of disease recurrence.
  68. ncbi Use of three-dimensional ultrasound in evaluating the intrauterine position of a levonorgestrel-releasing intrauterine system
    Efraim Zohav
    Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon, 78278, Israel
    Reprod Biomed Online 14:495-7. 2007
    ..reports the first case of three-dimensional (3-D) transvaginal ultrasonography (TVS) imaging of malpositioned levonorgestrel-releasing intrauterine system (LNG-IUS)...
  69. ncbi A randomized controlled trial of hysterectomy or levonorgestrel-releasing intrauterine system in the treatment of menorrhagia-effect on FSH levels and menopausal symptoms
    K Halmesmäki
    Department of Obstetrics and Gynecology, Central Hospital of Päijät Häme, Keskussairaalankatu 7, 15850 Lahti, Finland
    Hum Reprod 19:378-82. 2004
    The purpose of this study was to compare the effects of hysterectomy and a levonorgestrel-releasing intrauterine system (LNG-IUS) on serum FSH levels and menopausal symptoms.
  70. pmc Proultraflexible lipid vesicles for effective transdermal delivery of levonorgestrel: development, characterization, and performance evaluation
    Subheet Jain
    Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Punjab, India
    AAPS PharmSciTech 6:E513-22. 2005
    ..of new vesicular drug carrier system protransfersomes for transdermal delivery of the contraceptive agent, levonorgestrel. Protransfersome gel (PTG) formulations of levonorgestrel were prepared and characterized for vesicle shape, ..
  71. ncbi Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in chinese men
    You lun Gui
    Shanghai Institute of Planned Parenthood Research, 2140 Xie Tu Rd, Shanghai 200032, China
    J Androl 25:720-7. 2004
    ..degrees of sperm suppression in white men, we hypothesized that the combination of TU and the progestin levonorgestrel (LNG) would result in improved spermatogenic suppression in Chinese men...
  72. ncbi Assessment of menstrual blood loss in Belgian users of the frameless copper-releasing IUD with copper surface area of 200 mm2 and users of a copper-levonorgestrel-releasing intrauterine system
    D Wildemeersch
    Contrel Research, Ghent, Belgium
    Contraception 70:169-72. 2004
    This study was conducted to evaluate the effect of a miniaturized frameless copper IUD (GyneFix 200 small) and a copper-levonorgestrel (GynePlant) intrauterine system (IUS) on the amount of menstrual blood loss (MBL).
  73. ncbi The in vitro effect of emergency contraception doses of levonorgestrel on the acrosome reaction of human spermatozoa
    Karen Saboya Brito
    Human Reproduction Unit, Department of Obstetrics and Gynecology, School of Medicine, Universidade Estadual de Campinas UNICAMP, 13084 971 Campinas, Brazil
    Contraception 72:225-8. 2005
    The aim of this study was to evaluate the effect of three concentrations of levonorgestrel (LNG) comparable to the levels found in serum following ingestion of LNG as emergency contraception (EC) on the acrosome reaction (AR) of ..
  74. ncbi Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device
    Sergio Haimovich
    Department of Obstetrics and Gynecology, Hospital Universitari del Mar, Autonomous University of Barcelona, Barcelona, Spain
    Menopause 15:1002-4. 2008
    To assess the effectiveness of the Mirena levonorgestrel-releasing intrauterine system (LNG-IUS) in peri- and postmenopausal women with endometrial hyperplasia without atypia.
  75. ncbi The effect of levonorgestrel-releasing intrauterine system use on menstrual blood loss and the hemostatic, fibrinolytic/inhibitor systems in women with menorrhagia
    S C L Koh
    Department of Obstetrics and Gynaecology, National University of Singapore, Yong Loo Lin School of Medicine, National University Hospital, Singapore, Singapore
    J Thromb Haemost 5:133-8. 2007
    ..The levonorgestrel-releasing intrauterine system (LNG-IUS) ranks higher than medical treatments in terms of efficacy, comparable ..
  76. ncbi Levonorgestrel-releasing intrauterine system vs. endometrial thermal ablation for menorrhagia
    Theodoros D Theodoridis
    1st Department of Obstetrics and Gynaecology, Papageorgiou General Hospital, Aristotle University of Thessaloniki, Periferiaki Odos Thessalonikis, N Efkarpia, Thessaloniki, Greece
    Hormones (Athens) 8:60-4. 2009
    To evaluate the efficacy of a Levonorgestrel-releasing Intrauterine System (LNG-IUS) in controlling menorrhagia in comparison with endometrial thermal rollerball ablation.
  77. pmc Practice tips. Inserting the levonorgestrel intrauterine system: off-label use
    Catherine Caron
    Department of Family Medicine, University of Ottawa, Ontario
    Can Fam Physician 53:643-4. 2007
  78. ncbi A biodegradable levonorgestrel-releasing implant made of PCL/F68 compound as tested in rats and dogs
    Guilei Ma
    The Tianjin Key Laboratory of Biomaterials, Institute of Biomedical Engineering, Peking Union Medical College and Chinese Academy of Medical Sciences, Nankai District, Tianjin 300192, China
    Contraception 74:141-7. 2006
    ..Our objective was to report preclinical studies on a biodegradable long-acting contraceptive implant...
  79. ncbi A randomized trial of mifepristone (10 mg) and levonorgestrel for emergency contraception
    H Hamoda
    Department of Obstetrics and Gynaecology, University of Aberdeen, United Kingdom
    Obstet Gynecol 104:1307-13. 2004
    To compare the efficacy, patient acceptability and adverse effects of low-dose mifepristone (10 mg) with the levonorgestrel regimen (2 doses of 750 microg given 12 hours apart) for emergency contraception.
  80. ncbi Safety and efficacy of levonorgestrel implant, intrauterine device, and sterilization
    O Meirik
    United Nations Development Programme (UNDP)/United Nations Population Fund (UNFPA)/World Health Organization (WHO)/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Geneva, Switzerland
    Obstet Gynecol 97:539-47. 2001
    OBJECTIVE: To evaluate safety and efficacy of levonorgestrel-releasing contraceptive implants (Norplant; Leiras Oy, Turku, Finland) in developing countries. METHODS: We used controlled cohort methodology...
  81. ncbi The cost-effectiveness of the levonorgestrel-releasing intrauterine system for the treatment of idiopathic heavy menstrual bleeding in the United States
    Michael L Ganz
    United BioSource Corporation, Lexington, MA 02420, USA
    Value Health 16:325-33. 2013
    ..Our objective was to evaluate the cost-effectiveness of the levonorgestrel-releasing intrauterine system (LNG-IUS) compared with other therapies for idiopathic heavy menstrual bleeding.
  82. ncbi Efficacy of levonorgestrel intrauterine system (LNG-IUS) for abnormal uterine bleeding and contraception
    Nabia Tariq
    Department of Obstetrics and Gynaecology, Shifa College of Medicine, Islamabad
    J Coll Physicians Surg Pak 21:210-3. 2011
    To find out clinical response, side effects and patients' acceptability of levonorgestrel-releasing intrauterine system (LNG-IUS).
  83. ncbi The levonorgestrel-releasing intrauterine system provides a reliable, long-term treatment option for women with idiopathic menorrhagia
    Jan Endrikat
    Bayer HealthCare, Berlin, Germany
    Arch Gynecol Obstet 285:117-21. 2012
    Idiopathic menorrhagia (IM) is an important clinical challenge. The levonorgestrel-releasing intrauterine system (LNG IUS) provides an effective treatment option as shown by multiple small clinical studies...
  84. ncbi Management of endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: single arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2006)
    Taek Sang Lee
    Department of Obstetrics and Gynecology, Gangnam CHA Medical Center, CHA University, 650 9, Yoksam Dong, Gangnam Gu, Seoul 135 913, Republic of Korea
    Jpn J Clin Oncol 41:817-9. 2011
    A prospective multicenter trial has been commenced in Korea to investigate the treatment efficacy of the levonorgestrel-releasing intrauterine system in patients with endometrial hyperplasia...
  85. ncbi Pharmacokinetics of levonorgestrel 0.75 mg tablets
    Karin Kook
    Salamandra LLC, Chevy Chase, MD, USA
    Contraception 66:73-6. 2002
    This study examined plasma levonorgestrel (LNG) concentrations and pharmacokinetics following oral administration of a single LNG 0.75 mg tablet. Sixteen healthy female volunteers 19-44 years old enrolled in the study...
  86. pmc Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel
    Christine Klipping
    Dinox BV, Groningen, The Netherlands
    Drugs R D 11:159-70. 2011
    ..Based on previous studies, it is expected that this estradiol-based COC will have a reduced hepatic effect compared with COCs containing ethinylestradiol with regard to proteins controlling the hemostatic balance...
  87. ncbi Effect of mifepristone and levonorgestrel on expression of steroid receptors in the human Fallopian tube
    A Christow
    Division of Obstetrics and Gynecology, Department of Woman and Child Health, Karolinska Hospital, S 171 76 Stockholm, Sweden
    Mol Hum Reprod 8:333-40. 2002
    It is likely that mifepristone or levonorgestrel in the future will find extended use for contraceptive purposes. It is therefore essential to characterize the modes of action of these compounds...
  88. ncbi Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia
    Zeina J Haoula
    Department of Obstetrics and Gynaecology, University Hospital, Queens Medical Centre, Nottingham, NG7 2UH, United Kingdom
    Eur J Obstet Gynecol Reprod Biol 159:176-9. 2011
    The objective of this study was to evaluate the potential treatment of atypical and non-atypical endometrial hyperplasia with the levonorgestrel intrauterine system (LNG-IUS).
  89. ncbi Clinical outcome of levonorgestrel intra-uterine system in idiopathic menorrhagia
    B Chattopdhyay
    Department of Obstetrics and Gynaecology, Lady Hardinge Medical College, New Delhi, India
    Eur Rev Med Pharmacol Sci 15:764-8. 2011
    To evaluate the efficacy, acceptability and side effects of levonorgestrel intrauterine system in patients with idiopathic menorrhagia.
  90. ncbi The pharmacokinetics of 750 microg levonorgestrel following administration of one single dose or two doses at 12- or 24-h interval
    D Tremblay
    Laboratoire HRA Pharma, 19, , 75020 Paris, France
    Contraception 64:327-31. 2001
    The administration of two tablets of 750 microg levonorgestrel at a 12- to 24-h interval has been shown to be a safe and effective means of emergency contraception, and Norlevo/Vikela (N/V) is a dedicated product for this indication...
  91. ncbi Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII
    Marianne van Rooijen
    Department of Woman and Child Health, Division of Obstetrics and Gynaecology, King Gustaf V Research Institute, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden
    Am J Obstet Gynecol 186:44-8. 2002
    ..The objective of the study was to compare the effects of two different combined oral contraceptives on levels of plasma lipoproteins and coagulation factor VII...
  92. ncbi Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis
    S Hennessy
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Contraception 64:125-33. 2001
    ..and gestodene are associated with an increased risk of venous thromboembolism (VTE) versus OCs containing levonorgestrel. We were interested in synthesizing the available data, exploring explanations for mixed results, and ..
  93. ncbi The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraception
    Diana Mansour
    New Croft Centre, NE1 6ND Newcastle upon Tyne, UK
    Contraception 85:224-34. 2012
    The contraceptive profile of the levonorgestrel-releasing intrauterine system (LNG-IUS; Mirena®) is well established, with efficacy similar to that achieved with sterilization and rapid return to fertility after discontinuation of use...
  94. ncbi Ibuprofen prophylaxis for levonorgestrel-releasing intrauterine system insertion: a randomized controlled trial
    Julie Chor
    Department of Obstetrics and Gynecology, John H Stroger Jr Hospital of Cook County, Chicago, IL 60612, USA
    Contraception 85:558-62. 2012
    Despite the high efficacy of the levonorgestrel-releasing intrauterine system (LNG-IUS) in preventing pregnancy, uptake of the intrauterine devices remains low in the United States...
  95. ncbi The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study
    Alexandr I Pashov
    Department of Obstetrics and Gynecology, State Medical University n a V F Voyno Yasenetsky, Krasnoyarsk, Russia
    Gynecol Endocrinol 28:559-61. 2012
    ..After the third injection of 3.75 mg of leuproreline acetate, the levonorgestrel intrauterine hormonal system containing 52 mg levonorgestrel (Mirena®, Bayer, Germany) was inserted for at ..
  96. ncbi Circulating sex hormones and endometrial stromelysin-1 (matrix metalloproteinase-3) at the start of bleeding episodes in levonorgestrel-implant users
    E Marbaix
    Christian de Duve Institute of Cellular Pathology, Department of Pathology, Medical School of the Université catholique de Louvain, Bruxelles, Belgium
    Hum Reprod 15:120-34. 2000
    Unpredictable endometrial bleeding is the major side-effect of levonorgestrel-releasing s.c. implants (Norplant), otherwise a method of choice for long-term contraception...
  97. ncbi The synthetic progestogen, Levonorgestrel, but not natural progesterone, affects male mate calling behavior of Xenopus laevis
    Frauke Hoffmann
    Department of Ecophysiology and Aquaculture, Leibniz Institute of Freshwater Ecology and Inland Fisheries, Berlin, Germany
    Gen Comp Endocrinol 176:385-90. 2012
    ..to three environmentally relevant concentrations (10(-7) M, 10(-8) M and 10(-10) M) of the synthetic progestin Levonorgestrel (LNG) and the corresponding natural steroid progesterone (PRG), respectively...
  98. ncbi Cost-effectiveness and quality of life associated with heavy menstrual bleeding among women using the levonorgestrel-releasing intrauterine system
    Paul D Blumenthal
    Department of Obstetrics and Gynecology, Stanford University, Stanford, USA
    Int J Gynaecol Obstet 112:171-8. 2011
    To review the literature for economic and health-related quality of life outcomes data associated with the use of the levonorgestrel-releasing intrauterine system (LNG-IUS) in the management of heavy menstrual bleeding.
  99. ncbi The in vitro effect of levonorgestrel on the acrosome reaction of human spermatozoa from fertile men
    L Bahamondes
    Human Reproduction Unit, Department of Obstetrics and Gynecology, School of Medicine, Universidade Estadual de Campinas UNICAMP, Caixa Postal 6181, 13084 971, Campinas, Sao Paulo, Brazil
    Contraception 68:55-9. 2003
    The objective of the study was to evaluate the effect of levonorgestrel (LNG) on the occurrence of acrosome reaction (AR) of capacitated spermatozoa from fertile men. A total of 20 semen samples from four fertile men were evaluated...
  100. ncbi Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial
    Prasong Tanmahasamut
    Gynecologic Endocrinology Unit, Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
    Obstet Gynecol 119:519-26. 2012
    To estimate the effectiveness of a postoperative levonorgestrel-releasing intrauterine system for relieving pelvic pain in patients with endometriosis.
  101. ncbi Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system
    Takeshi Maruo
    Kobe Children s Hospital and Feto Mternal Medical Center, Kobe 654 0081, Japan
    Contraception 82:435-41. 2010
    The use of levonorgestrel-releasing intrauterine system (LNG-IUS) is effective for management of menorrhagic women with uterine myomas because of reduction in menorrhagia...

Research Grants63

  1. Safety and Acceptability of Two IUDs among Cape Town HIV-positive Women: A RCT
    CATHERINE SUZANNE TODD; Fiscal Year: 2013
    ..The levonorgestrel intrauterine device (LNG IUD) is a long-acting, highly effective contraceptive method with largely localized ..
  2. Inhibitors of Mycobacterial Protein Tyrosine Phosphatase B (mPTPB) for therapy of
    Francis Burrows; Fiscal Year: 2013
    ..complete a standard screen to identify a clinical formulation, determine oral bioavailability and perform preliminary toxicology in the rat (iv) To identify potential backup compounds from pre-existing libraries of PTP inhibitors ..
  3. Quantification of Immune Cells in Women Using Contraception
    SHARON LYNELLE ACHILLES; Fiscal Year: 2013
    ..1) combined oral contraceptive pills, (2) depot medroxyprogesterone acetate (Depo-Provera(R)), (3) a levonorgestrel intrauterine device (Mirena(R)), or (4) a copper intrauterine device (ParaGard(R)), plus 25 women using ..
  4. Emergency Contraception to Prevent Pregnancy: Missed Opportunities for Care.
    MICHELLE LYNNE MUNRO; Fiscal Year: 2012
    ....
  5. Factors That Affect Endometrial Immunity: Implications for HIV Infection
    Joseph C Chen; Fiscal Year: 2012
    ..g. Depo-Provera and the levonorgestrel intrauterine system) increase the HIV infection rate...
  6. Modulation of Hormonal and Systemic Immunity by Hormonal Contraceptive Use
    Thomas L Cherpes; Fiscal Year: 2013
    ..to this research question that focuses on the immunomodulatory effects of DMPA, oral contraceptives (OC), and levonorgestrel-containng intrauterine devices (LNG-IUD) that may impair host responses against viral pathogens...
  7. Obesity Prevention Tailored for Health II
    KIM DANIEL REYNOLDS; Fiscal Year: 2012
    ..Two 24-hour recalls will be completed at each assessment period. BMI and physical activity will be objectively measured through height and weight assessments, and through the use of accelerometry to assess physical activity. ..
  8. Implementing Comprehensive PMTCT and HIV Prevention for South African Couples
    KARL F PELTZER; Fiscal Year: 2013
    ....
  9. Evaluation of the immunologic and genital tract changes among Malawian women
    Jennifer Tang; Fiscal Year: 2013
    ..Understanding the potential association between progestins (such as medroxyprogesterone or levonorgestrel) and HIV acquisition is currently a critical research priority for women's health researchers and ..
  10. A pharmacokinetic evaluation of levonorgestrel implant and antiretroviral therapy
    Kimberly K Scarsi; Fiscal Year: 2013
    ..gap in knowledge, the overall aim of this proposal i to conduct a PK study to evaluate the combination of a levonorgestrel (LNG) implant and NNRTI (nevirapine or efavirenz)-based ART in HIV-infected Ugandan women...
  11. EC Method: Determinants for Copper IUD Use and Future Unintended Pregnancy
    David Turok; Fiscal Year: 2011
    DESCRIPTION (provided by applicant): Widely available oral levonorgestrel for emergency contraception (EC) has not reduced unplanned pregnancy rates...
  12. A novel vaginal ring to prevent HIV and HSV-2 infection, as well as pregnancy
    THOMAS MICHAEL ZYDOWSKY; Fiscal Year: 2013
    ..two anti-HIV agents (1 of 2 novel NNRTIs and zinc acetate, ZA) and a low dose progestin only contraceptive (Levonorgestrel, LNG)...
  13. Levonorgestrel intrauterine system versus oral contraceptives for heavy menses
    Kristen A Matteson; Fiscal Year: 2013
    ..In the United States, combined oral contraceptives and the levonorgestrel intrauterine system are the two most commonly prescribed non-surgical treatments for heavy menstrual bleeding...
  14. CLINICAL EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION
    Jeffrey Jensen; Fiscal Year: 2011
    ..A new long acting formulation of Levonorgestrel Butanoate (LB), delivered by injection, has been developed...
  15. Prevention of HIV transmission/acquisition through informed contraceptive choice
    Danny J Schust; Fiscal Year: 2013
    ..As alternatives to DMPA, levonorgestrel (LNG), nomegestrel acetate (NOMAC) and the PR modulator, ulipristal (UL), have poor affinity for the GR and ..
  16. Goals of Care: A Nursing Home Trial of Decision Support for Advanced Dementia
    Laura C Hanson; Fiscal Year: 2013
    ..To permit dissemination, the intervention design is pragmatic and well integrated with nursing home interdisciplinary care. ..
  17. ENDOMETRIAL VEGF: ENDOCRINE REGULATION OF ANGIOGENESIS
    Robert Taylor; Fiscal Year: 1999
    ..underly irregular bleeding commonly associated with depot medroxyprogesterone acetate (DMPA) injections and levonorgestrel- containing silastic capsules (Norplant)...
  18. PHARMACOKINETIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION
    Jeffrey Jensen; Fiscal Year: 2011
    ..A new long acting formulation of Levonorgestrel Butanoate (LB), delivered by injection, has been developed...
  19. Piloting a Mobile App for HIV Risk Reduction among Young Latinas &Black Females
    SONIA K GONZALEZ; Fiscal Year: 2013
    ....
  20. HORMONE ASSAYS FOR THE DOSE FINDING STUDY FOR LEVONORGESTREL BUTANOATE
    Jeffrey Jensen; Fiscal Year: 2011
    ..A new long acting formulation of Levonorgestrel Butanoate (LB), delivered by injection, has been developed...
  21. NORPLANT USE BY LOW-INCOME WOMEN
    Leslie Clarke; Fiscal Year: 1993
    ..This study responds to the need for research on new contraceptive methods and the need for reductions in unintended pregnancies in the U.S. as set forth in Healthy People 2000. ..
  22. UNDERSTANDING OVARIAN CONTROL IN RARE BIOMEDICAL MODELS
    KATHARINE PELICAN; Fiscal Year: 2006
    ..leuprolide acetate (Lupron), a gonadotropin releasing hormone (GnRH) agonist; 2) Antide, a GnRH antagonist; 3) levonorgestrel (Norplant), a progestogen implant; and 4) altrenogest (Regumate), an oral progestogen...
  23. CCTN-CLINICAL EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION
    Kurt Barnhart; Fiscal Year: 2011
    ..A new long acting formulation of Levonorgestrel Butanoate (LB), delivered by injection, has been developed...
  24. A RCT of LNG-IUD vs. DMPA for young postpartum women
    Nancy Stanwood; Fiscal Year: 2005
    ..The levonorgestrel intrauterine device (LNG-IUD) is a very effective, well-tolerated contraceptive...
  25. Family Planning Promotion in HIV Infected Zambians
    Susan Allen; Fiscal Year: 2005
    ..Cost- effectiveness will be determined with methods developed jointly by experts in the fields of HIV therapy in Africa and contraception. ..
  26. Mifepristone for Prevention of Breakthrough Bleeding
    John Jain; Fiscal Year: 2004
    ..Mifepristone has been shown to decrease breakthrough bleeding in women using levonorgestrel implants...
  27. Suppression of Breakthrough Bleeding in LNG-IUS Users
    Ov Slayden; Fiscal Year: 2006
    ..provided by applicant): The Mirena(c) (Leiras, OY, Finland) is an intrauterine system (IUS) that releases levonorgestrel (LNG) and provides women with highly effective contraception for 5 years...
  28. CLINICAL EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION
    David Archer; Fiscal Year: 2011
    ..The objective of the dose finding study is to identify a dose that can provide reliable contraception and acceptable bleeding patterns for up to 6 months of use. ..
  29. ADOLESCENT MISCONCEPTIONS ABOUT HORMONAL CONTRACEPTION
    LIANA CLARK; Fiscal Year: 2003
    ..Increased usage and improved compliance with Depo-Provera, Norplant and the oral contraceptive pill will result in an overall decrease in the rate of unintended adolescent pregnancy. ..
  30. St. John's Wort Effects on Levonorgestrel
    Patricia Murphy; Fiscal Year: 2006
    ..John's Wort (Hypericum perforatum), on metabolism of levonorgestrel in a dosing regimen for emergency contraception...
  31. CLINICAL EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION
    Michael Thomas; Fiscal Year: 2011
    ..A new long acting formulation of Levonorgestrel Butanoate (LB), delivered by injection, has been developed...
  32. BIODEGRADABLE LEVONORGESTREL CONTRACEPTIVE IMPLANTS
    Larry Nichols; Fiscal Year: 2000
    b>Levonorgestrel is a steroid widely used for fertility regulation...
  33. Web Based Intervention for African American Mothers
    Diane Brage Hudson; Fiscal Year: 2005
    ..Subjects will be randomly assigned to the Experimental Group and the Control Group. Descriptive summary statistics, repeated measures analysis of co-variance, and reliability indices will be used to test the study aims. ..
  34. CONTROLLED RELEASE OF ATRIAL NATRIURETIC FACTOR
    Maria Rupnick; Fiscal Year: 2001
    ..End of Abstract) ..
  35. Clinical Translational Research in Transplant Nephrology
    Bryan Becker; Fiscal Year: 2006
    ..It will also work to meet the NIH's goal of increasing the number of physician-scientists conducting high-quality patient-oriented research. ..
  36. Novel Controlled Delivery Systems for Contraceptives
    Jagdish Singh; Fiscal Year: 2005
    ..by 1H NMR; (2) To prepare in situ gel forming smart polymer solution based controlled delivery systems for levonorgestrel and testosterone, using phase sensitive and temperature sensitive polymers; (3) To study in vitro release ..
  37. EXPANSION OF CHIMPANZEE HOLDING FACILITIES
    Thomas Rowell; Fiscal Year: 1999
    ..disrupting family groups or permanently altering male or female animals assigned to the program by applying levonorgestrel implants in breeding age females...
  38. TRANSDERMAL LEVONORGESTREL FOR EMERGENCY CONTRACEPTION
    Larry Nichols; Fiscal Year: 1999
    This program will attempt to develop a transdermal system capable of delivering enough levonorgestrel in 24 hours to provide emergency postcoital contraception as effective as currently approved oral methods, but with greater convenience ..
  39. NOVEL RADIOTRACERS FOR ANDROGEN RECEPTOR IMAGING
    MARCIAN VAN DORT; Fiscal Year: 2001
    ..abstract_text> ..
  40. Conspiracies, Perceived Discrimination & Sexual Behavior
    Sheryl Thorburn; Fiscal Year: 2003
    ..Findings from this study will inform efforts to prevent HIV and other STDs, as well as unintended pregnancy, among African Americans nationally. ..
  41. NONLINEAR DYNAMICAL ANALYSIS OF TEEN BIRTHS IN TEXAS
    Patti Hamilton; Fiscal Year: 2000
    ..Through more complete and accurate analysis, more effective policy, and interventions can be designed, implemented and evaluated. ..
  42. BIOERODIBLE NARCOTIC ANTAGONIST DELIVERY DEVICE
    Jorge Heller; Fiscal Year: 1990
    ..Poly(ortho esters) have been extensively investigated by the principal Investigator for the release of levonorgestrel, and toxicological studies for an IND filing are about to be initiated...
  43. PREPAID COMMUNITY MENTAL HEALTH SERVICES PLAN
    TODD SCHAIBLE; Fiscal Year: 1980
    ....
  44. A One Year Estrogen/Progestin Implant
    Larry Nichols; Fiscal Year: 2003
    ..Estradiol plus levonorgestrel will be incorporated into an innovative implant design already being developed by BIOTEK for delivery of pure ..
  45. TRANSDERMAL LEVONORGESTREL FOR EMERGENCY CONTRACEPTION
    Larry Nichols; Fiscal Year: 2002
    ..applicant's description): This program seeks to develop a transdermal system capable of delivering 1,500 ug of levonorgestrel over the course of 24 hours through two 30 cm2 patches...
  46. AN ESTROGEN-PROGESTIN PATCH FOR ESTROGEN REPLACEMENT
    ELIE NUWAYSER; Fiscal Year: 1991
    ..drug delivery system for the development of a sustained transdermal delivery system for estradiol and levonorgestrel for use in estrogen replacement therapy...
  47. ONE YEAR ESTROGEN/PROGESTIN IMPLANT
    Larry Nichols; Fiscal Year: 1999
    ..The program will utilize a proven hormone combination, estradiol and levonorgestrel. It has been shown that side effects of estrogen therapy can be lowered by administering a progestin with the ..
  48. CONTRACEPTIVE CLINICAL TRIAL NETWORK (FEMALE)
    Mark Carter; Fiscal Year: 2011
    ..Specifically, the levonorgestrel patch.
  49. CONTRACEPTIVE CLINICAL TRIALS NETWORK (FEMALE)
    BRADFORD SEAMON; Fiscal Year: 2011
    ..Specifically, the levonorgestrel patch.
  50. CONTRACEPTIVE CLINICAL TRIALS NETWORK (FEMALE)
    DORISA HARRIS; Fiscal Year: 2011
    ..Specifically,, the levonorgestrel patch.
  51. DOXYCYCLINE FOR BLEEDING IN PROGESTIN ONLY CONTRACEPTORS
    David Archer; Fiscal Year: 2006
    ..If successful, DOX treatment could become an important adjuvant for treatment of this and possibly other inflammatory disorders effecting reproductive tract tissues. ..
  52. PDE3 Inhibitors: Selective Blockers of Oocyte Maturation
    Jeffrey Jensen; Fiscal Year: 2007
    ..This approach is expected to provide a foundation for future Phase 1 trials of PDE3 inhibitors in humans. ..